The Prescribing Information for Reminyl [galantamine] has been updated

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2005年 / 1046卷 / 1期

关键词：

Public Health; Placebo; Clinical Trial; Healthcare Professional; Galantamine;

D O I：

10.2165/00128415-200510460-00011

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[1] The US prescribing information for RotaTeq [rotavirus W179-9 vaccine] has been updated
Reactions Weekly, 2007, 1140 (1) : 3 - 3
[2] The Avelox [moxifloxacin] prescribing information has been updated to warn of the risk of potentially fatal liver failure and toxic epidermal necrolysis
Reactions Weekly, 2007, 1178 (1) : 5 - 5
[3] Bevacizumab [Avastin] safety information has been updated in Canada
Reactions Weekly, 2011, 1378 (1) : 3 - 3
[4] `Risperdal' prescribing information updated
Reactions Weekly, 2003, 949 (1) : 2 - 2
[5] Treatment options:: The latest evidence with galantamine (Reminyl®)
Erkinjuntti, T
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 203 : 125 - 130
[6] Zonisamide prescribing information updated
Reactions Weekly, 2002, 911 (1) : 2 - 2
[7] Prescribing information updated for Rho(D) immunoglobulin
Reactions Weekly, 2000, 785 (1) : 2 - 2
[8] Topiramate prescribing information updated
Reactions Weekly, 2001, 872 (1) : 2 - 2
[9] CellCept prescribing information updated
Reactions Weekly, 2009, 1266 (1) : 2 - 2
[10] The pharmacological rationale for treating vascular dementia with galantamine (ReminylΤΜ)
Maelicke, A
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2001, : 24 - 28

← 1 2 3 4 5 →